These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37787866)

  • 1. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
    Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
    Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
    Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
    ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
    Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
    Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
    Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
    Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
    Swain SM; Nishino M; Lancaster LH; Li BT; Nicholson AG; Bartholmai BJ; Naidoo J; Schumacher-Wulf E; Shitara K; Tsurutani J; Conte P; Kato T; Andre F; Powell CA
    Cancer Treat Rev; 2022 May; 106():102378. PubMed ID: 35430509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
    Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
    Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.
    Henning JW; Brezden-Masley C; Gelmon K; Chia S; Shapera S; McInnis M; Rayson D; Asselah J
    Curr Oncol; 2023 Aug; 30(9):8019-8038. PubMed ID: 37754497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
    Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
    Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab Deruxtecan‒Related Interstitial Lung Disease/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management.
    Nishino M; Kusumoto M; Bankier AA; Kurihara Y; Zhang L; Rasheed Z; Meinhardt G; Arunachalam M; Taitt C; Wang Q; Powell CA
    JCO Precis Oncol; 2023 Sep; 7():e2300391. PubMed ID: 38061008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
    Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
    Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.
    Wekking D; Porcu M; Pellegrino B; Lai E; Mura G; Denaro N; Saba L; Musolino A; Scartozzi M; Solinas C
    ESMO Open; 2023 Dec; 8(6):102043. PubMed ID: 37951130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
    Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
    Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report.
    de Weger VA; Schutte T; Konings IRHM; Menke-van der Houven van Oordt CW
    J Breast Cancer; 2023 Oct; 26(5):519-523. PubMed ID: 37926069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
    Shitara K
    Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
    Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
    ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
    Nonomiya Y; Nakayama I; Kobayashi K; Amakawa Y; Shibata N; Soejima A; Kawakami K; Shimizu H; Takahari D; Kawai S; Hara F; Takano T; Yamaguchi K; Yamaguchi M
    Biol Pharm Bull; 2024; 47(2):411-416. PubMed ID: 38346748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.